Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.51 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28577719 | 0.96 | PDE4B (0.52) | PDE4BSLC6A11SLC6A1HTTNPSR1 | |
| SCHEMBL12004703 | 0.94 | PDE4B (0.51) | PDE4BSLC6A11SLC6A1HTTNPSR1 | |
| SCHEMBL12004675 | 0.94 | PDE4B (0.51) | PDE4BSLC6A11SLC6A1HTTNPSR1 | |
| SCHEMBL12005099 | 0.94 | PDE4B (0.51) | PDE4BSLC6A11SLC6A1HTTNPSR1 | |
| SCHEMBL6838786 | 0.92 | PDE4B (0.47) | PDE4BSLC6A11SLC6A1HTTNPSR1 | |
| SCHEMBL30861823 | 0.91 | SLC6A11 (0.53) | PDE4BSLC6A11SLC6A1HTTNPSR1 | |
| SCHEMBL8870562 | 0.88 | KIF11 (0.53) | SLC6A1KIF11FFAR4 | |
| SCHEMBL335718 | 0.87 | SLC6A11 (0.46) | PDE4BSLC6A11SLC6A1HTTNPSR1 | |
| SCHEMBL2837142 | 0.87 | SLC6A11 (0.46) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL13551201 | 0.87 | GAA (0.48) | SLC6A11SLC6A1MEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762281-B2 | GENERATING PREFERENTIAL OLIGOMERS; GENERATE OLIGOMER, DEPROTECT, EXPOSE TO PHOSPHOROUS, OXIDIZE, EXPOSE TO SULFUR, CLEAVE, RECOVER PRODUCT | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| US-20040019000-A1 | Polyalkyleneamine-containing oligomers | ISIS PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-6559279-B1 | Generation of peptide linked oligomers; generate solid support, expose to deprotecting agent, incubate with nucleoside, cap, cleave and recover peptide derivative | ISIS PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002020544-A1 | PROCESS FOR PREPARING PEPTIDE DERIVATIZED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IAPP, PTMS, NGLY1 | PDE4B 4549/4885SLC6A11 4309/4885SLC6A1 4635/4885 |
| US-20040019000-A1 | Polyalkyleneamine-containing oligomers | FUS, NSF, PICALM | PDE4B 4722/4885SLC6A11 383/4885SLC6A1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.